Weight Loss Products

Approx. Rs 16,500 / VialGet Latest Price

Product Details:

The Retatrutide pen is used for once-weekly subcutaneous injections, primarily to treat obesity/overweight and manage type 2 diabetes.

Approx. Rs 14,000 / VialGet Latest Price

Product Details:

Retatrutide 60mg Pen refers to an investigational, injectable medication for weight loss, a triple-agonist targeting GIP, GLP-1, and glucagon receptors, showing significant weight reduction in trials by reducing appetite and increasing metabolism, available in pre-filled pens for weekly subcutaneous use, though still under development and not yet FDA-approved for general use. Suppliers in India offer it in pen form for research/export, often citing 12mg strength pens with potential doses up to 60mg or more, mimicking similar drugs like Ozempic but with a triple-hormone approach for potentially greater efficacy. What it is

• A Triple-Agonist: It mimics three natural gut hormones (GIP, GLP-1, and glucagon) to control hunger, slow digestion, and boost fat burning.
• Investigational Drug: Still in clinical trials (Phase 3), not approved by regulatory bodies like the FDA for public use yet. 

How it's used

• Weekly Injection: Administered once a week under the skin (subcutaneously).
• Pen Device: Comes in a pen format for easier dosing, similar to Ozempic or Mounjaro.
• Dosage: Doses studied range from 1mg to 12mg, with higher doses potentially leading to greater weight loss. 

What it does

• Significant Weight Loss: Phase 2 trials showed average weight loss of over 20% in 48 weeks.

Approx. Rs 11,000 / VialGet Latest Price

Product Details:

Retatrutide is an experimental medication for weight loss and type 2 diabetes that is administered via weekly subcutaneous injection using a pen device. It works as a triple receptor agonist, targeting glucagon, GLP-1, and GIP receptors to increase feelings of fullness, regulate blood sugar, and boost metabolism. The most common side effects are gastrointestinal, including nausea, vomiting, and diarrhea

Approx. Rs 3,000 / VialGet Latest Price

Product Details:

A first-of-its-class triple receptor agonist, retatrutide, aims to deliver a revolution in obesity and T2DM pharmacotherapy. This groundbreaking medication is shown to enhance therapeutic outcomes by delivering more pronounced reductions in both body weight and HbA1c levels than current pharmacotherapies.